Jean-Marc Bellemin - Mar 3, 2025 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Financial Officer
Signature
/s/ Jean-Marc Bellemin
Stock symbol
IOVA
Transactions as of
Mar 3, 2025
Transactions value $
-$128,205
Form type
4
Date filed
3/5/2025, 08:33 PM
Previous filing
Sep 5, 2024
Next filing
Mar 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +58.6K +199.64% $0.00 87.9K Mar 3, 2025 Direct F1, F2
transaction IOVA Common Stock Tax liability -$128K -31.7K -36.09% $4.04 56.2K Mar 3, 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -58.6K -45.45% $0.00 70.3K Mar 3, 2025 Common Stock 58.6K Direct F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2 Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
F3 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F4 Represents common stock remaining after deducting the common stock withheld for taxes.
F5 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F6 The remaining RSUs will vest in equal quarterly installments.
F7 Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.